New hope for hard-to-treat colon cancer: drug combo targets RAS mutation
NCT ID NCT06936527
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a new drug called XS-03 combined with standard chemotherapy and a targeted therapy (bevacizumab) in people with metastatic colorectal cancer that has a RAS mutation. About 102 adults aged 18-70 will take part. The goal is to see if the combination is safe and works better at shrinking tumors than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.